A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Clinical trial NCT07422753 · RECRUITING
Trial details
- NCT number
- NCT07422753
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-25
- Primary completion
- 2027-03-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.